Updated:
PAREXEL International Corporation
PAREXEL International Corporation is a asset manager based in Durham; the Altss profile covers its classification, headquarters, registration, AUM band, and...
PAREXEL International Corporation
For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Principals
Chris Learn
Vice President, Cell and Gene Therapy, Center of Excellence
Steve Winitsky
Senior Vice President
Stefan Zietze
Executive Director
Hicham El Bariqi
Director, Cell & Gene Therapy
Jingke Yang
Senior Medical Director
Sector focus
Frequently asked questions
Who runs investment decisions at PAREXEL International?
PAREXEL is a clinical research organization rather than an investment firm. The leadership team is composed of executives such as Senior Vice President Steve Winitsky and Vice President Chris Learn, who oversee the firm's cell and gene therapy and other therapeutic areas (per the firm's website). Strategic and operational decisions are made by the executive leadership, whose full roster is listed on the firm's about page.
How does PAREXEL source proprietary deal flow?
As a contract research organization, PAREXEL does not follow a traditional investment deal flow model. The firm generates revenue by providing clinical development services to biopharmaceutical clients, including Phase I-IV trials, regulatory strategy, and market access planning. Client relationships are built through its therapeutic expertise and global operational reach.
Is PAREXEL structured as a single family office or does it operate more like a venture firm?
PAREXEL International is a publicly traded contract research organization (CRO), not a family office or venture capital firm. It operates as a service provider to the biopharmaceutical industry, managing clinical trials and drug development processes. The firm does not deploy capital as an allocator.
Does PAREXEL participate in fund commitments or only direct deals?
PAREXEL does not participate in fund commitments or direct investments. The firm's business model is based on providing clinical research services, including clinical trials, regulatory consulting, and market access support, to pharmaceutical and biotechnology companies. Its revenue comes from service contracts, not from capital allocation.
What investment stages does PAREXEL typically target?
PAREXEL specializes in clinical development services spanning Phase I through Phase IV trials. This covers early-stage investigational drug studies through post-market surveillance. The firm also offers portfolio management and asset valuation, early development and innovation, and approval and access support.
Which sectors does PAREXEL explicitly avoid?
The firm does not publicly disclose excluded sectors. Its stated therapeutic areas include neuroscience, general medicine, infectious disease and vaccines, immunology, oncology, hematology, ophthalmology, cell and gene therapies, pediatrics, and rare diseases. No explicit avoided sectors are listed.
Where does the underlying wealth come from?
PAREXEL is a publicly traded corporation, not a family office. Its revenue is generated through client contracts for clinical research services. The firm does not manage external wealth or disclose a wealth origin outside the context of its own corporate finances.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: